FDA advisory committee recommends six peptides for the 503A bulks list

The FDA's Pharmacy Compounding Advisory Committee (PCAC) closed its July 23-24, 2026 meeting by narrowly recommending six of seven peptides under review — BPC-157, KPV, TB-500, MOTS-c, Semax and epitalon — for the agency's 503A Bulks List, the roster of bulk ingredients that compounding pharmacies may legally use ^[1]. The panel went against FDA's own scientific staff, who had recommended against adding any of the seven ^[1][2].

The margins were thin. On July 23, the committee voted 8-6 with one abstention to recommend BPC-157, KPV and TB-500, and 7-5 with two abstentions on MOTS-c ^[1]. Semax and epitalon cleared on July 24 by similarly tight margins ^[1]. The only rejection was emideltide, also called delta sleep-inducing peptide, voted down 7-6 with one abstention ^[1]. Observers described an audible gasp when the first tally was read, noting that a PCAC panel had rarely, if ever, voted against FDA staff's written recommendation ^[1].

None of the seven substances reviewed is a GLP-1 medicine, and none of them is an FDA-approved drug ^[1]. FDA reviewers' briefing materials concluded that available studies — including five trials of BPC-157 — were short, small and insufficient to establish safety or effectiveness for the proposed uses, which spanned ulcerative colitis, wound healing, obesity, osteoporosis and opioid withdrawal ^[1]. The reconstituted panel's roster drew scrutiny for including more health professionals who prescribe, produce or promote peptides than earlier versions of the committee, which had been made up mainly of academics and researchers ^[1].

A recommendation is not permission

The votes did not amend the 503A Bulks List ^[2]. PCAC is advisory; FDA decides what goes on the list, and the agency is not legally required to adopt any recommendation ^[2]. If FDA agrees, it must still publish a proposed rule, take public comments, and issue a final rule before these peptides could be legally compounded ^[1][2]. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, noted that FDA must formally adopt the advisers' recommendations first ^[1]. HHS Secretary Robert F. Kennedy Jr., who has called himself "a big fan" of peptides, could try to speed that up, though experts say the timeline is unclear ^[1].

One law firm analysis points out how slow this process has been historically: FDA published a proposed rule covering ten other bulk substances in December 2016 and did not issue the final rule until February 2019 — more than two years later, placing six substances on the list and rejecting four ^[2]. There is no statutory deadline for FDA to act after a PCAC vote ^[2]. A separate question is FDA's interim enforcement posture: under the older framework, "Category 1" substances got a limited bridge while review continued, but FDA changed that in January 2025 so that substances newly nominated on or after January 7, 2025 are no longer assigned to Categories 1, 2 or 3 ^[2].

Why it matters for patients

Many people taking GLP-1 medicines encounter peptides like BPC-157 and TB-500 through the same telehealth, wellness and online channels that sell compounded weight-loss drugs. This vote does not make those products approved, tested or legal to compound ^[1][2]. BPC-157 and TB-500 are classified as doping substances by international sports authorities and remain widely sold online under "research use only" disclaimers despite FDA restrictions imposed in 2023 ^[1].

Cost is another practical point. Compounded drugs generally fall outside standard pharmacy benefit coverage, so even if a final rule eventually takes effect, patients would likely keep paying cash ^[1]. Analysts advising health plans said they expect continued use of peptides bought from unregulated online sellers in the meantime, and urged careful medication reconciliation and adverse-event monitoring given the limited human safety data FDA's own reviewers cited ^[1].

What happens next

• July 23-24, 2026: PCAC votes; six peptides recommended, emideltide rejected ^[1].
• Next: FDA decides whether to accept, reject, add conditions, request more data, or simply take more time ^[2]. No date has been set, and the sources say no reliable timetable exists ^[2].
• If FDA proceeds: a proposed rule, a public comment docket, then a final rule ^[1][2].

Whether FDA will revisit its interim enforcement stance on these substances before rulemaking finishes is not yet known ^[2].